首页> 外文期刊>Journal of the American Society for Mass Spectrometry >DMSO Assisted Electrospray Ionization for the Detection of Small Peptide Hormones in Urine by Dilute-and-Shoot-Liquid-Chromatography-High Resolution Mass Spectrometry
【24h】

DMSO Assisted Electrospray Ionization for the Detection of Small Peptide Hormones in Urine by Dilute-and-Shoot-Liquid-Chromatography-High Resolution Mass Spectrometry

机译:DMSO通过稀释 - 液相色谱 - 高分辨率质谱法辅助电喷雾电离检测尿液中的小肽激素

获取原文
获取原文并翻译 | 示例
           

摘要

The mobile phase additive (DMSO) has been described as a useful tool to enhance electrospray ionization (ESI) of peptides and proteins. So far, this technique has mainly been used in proteomic/peptide research, and its applicability in a routine clinical laboratory setting (i.e., doping control analysis) has not been described yet. This work provides a simple, easy to implement screening method for the detection of doping relevant small peptides (GHRPs, GnRHs, GHS, and vasopressin-analogues) with molecular weight less than 2 kDa applying DMSO in the mobile phase. The gain in sensitivity was sufficient to inject the urine samples after a 2-fold dilution step omitting a time consuming sample preparation. The employed analytical procedure was validated for the qualitative determination of 36 compounds, including 13 metabolites. The detection limits (LODs) ranged between 50 and 1000 pg/mL and were compliant with the 2 ng/mL minimum detection level required by the World Anti-Doping Agency (WADA) for all the target peptides. To demonstrate the feasibility of the work, urine samples obtained from patients who have been treated with desmopressin or leuprolide and urine samples that have been declared as adverse analytical findings were analyzed.
机译:移动相添加剂(DMSO)已被描述为增强肽和蛋白质的电喷雾电离(ESI)的有用工具。到目前为止,该技术主要用于蛋白质组学/肽研究,其在常规临床实验室设置(即掺杂控制分析)中的适用性尚未描述。这项工作提供了一种简单,易于实施的筛选方法,用于检测掺杂相关的小肽(GHRPS,GnRHS,GHS和VasoPressin-类似物),其中分子量小于2kDa在流动相中施加DMSO。在省略耗时的样品制备时,在稀释时间后,敏感性的增益足以注入尿液样品。验证了所用的分析程序,用于定性测定36种化合物,其中包括13种代谢物。检测限制(LOD)范围为50至1000pg / ml,并符合世界反掺杂机构(WADA)对所有靶肽所需的2ng / ml最小检测水平。为了证明作品的可行性,分析了从已宣布为不利分析结果的去解压素或雌醇苷和尿液样本治疗的患者中获得的尿样。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号